These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 7545119

  • 1. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
    Cayeux S, Beck C, Aicher A, Dörken B, Blankenstein T.
    Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [Abstract] [Full Text] [Related]

  • 4. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
    Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH.
    Cell Immunol; 2001 May 25; 210(1):56-65. PubMed ID: 11485353
    [Abstract] [Full Text] [Related]

  • 5. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1996 Aug 25; 26(8):1851-9. PubMed ID: 8765031
    [Abstract] [Full Text] [Related]

  • 6. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
    Cayeux S, Richter G, Noffz G, Dörken B, Blankenstein T.
    J Immunol; 1997 Mar 15; 158(6):2834-41. PubMed ID: 9058819
    [Abstract] [Full Text] [Related]

  • 7. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Kuzushita N, Ito A, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Hepatology; 1999 Aug 15; 30(2):422-9. PubMed ID: 10421650
    [Abstract] [Full Text] [Related]

  • 8. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y, McGowan P, Hellström I, Hellström KE, Chen L.
    J Immunol; 1994 Jul 01; 153(1):421-8. PubMed ID: 7515929
    [Abstract] [Full Text] [Related]

  • 9. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E, Aruga A, Arca MJ, Lee WM, Yang NS, Smith JW, Chang AE.
    Cancer Gene Ther; 1997 Jul 01; 4(3):157-66. PubMed ID: 9171934
    [Abstract] [Full Text] [Related]

  • 10. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M.
    J Immunol; 1999 Mar 15; 162(6):3574-82. PubMed ID: 10092816
    [Abstract] [Full Text] [Related]

  • 11. Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice.
    Li Y, Newby SA, Johnston JV, Hellström KE, Chen L.
    J Immunol; 1995 Dec 15; 155(12):5705-10. PubMed ID: 7499857
    [Abstract] [Full Text] [Related]

  • 12. Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
    Liu X, Zhang L, Zhang M, Ma Y, Xu X, Cai Y.
    Chin Med J (Engl); 2000 Feb 15; 113(2):167-71. PubMed ID: 11775545
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules.
    Liu Y, Wang H, Zhao J, Ma J, Wei L, Wu S, Xie T, Shen F, Trojan J, Habib N, Anthony DD, Wu M, Guo Y.
    Cancer Gene Ther; 2000 Mar 15; 7(3):456-65. PubMed ID: 10766352
    [Abstract] [Full Text] [Related]

  • 14. Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant.
    Cayeux S, Beck C, Dörken B, Blankenstein T.
    Hum Gene Ther; 1996 Mar 01; 7(4):525-9. PubMed ID: 8800747
    [Abstract] [Full Text] [Related]

  • 15. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.
    Chen L, McGowan P, Ashe S, Johnston JV, Hellström I, Hellström KE.
    Cancer Res; 1994 Oct 15; 54(20):5420-3. PubMed ID: 7522958
    [Abstract] [Full Text] [Related]

  • 16. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL.
    Cancer Res; 1995 Nov 01; 55(21):4980-7. PubMed ID: 7585539
    [Abstract] [Full Text] [Related]

  • 17. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.
    Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT.
    Eur J Immunol; 1996 Jun 01; 26(6):1335-41. PubMed ID: 8647214
    [Abstract] [Full Text] [Related]

  • 18. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE, Su FW, Atherton JM, Allison JP.
    Cancer Res; 1994 Dec 15; 54(24):6477-83. PubMed ID: 7527298
    [Abstract] [Full Text] [Related]

  • 19. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
    Wang J, Nakamoto T, Kasaoka Y, Usui T, Hamada H.
    Hiroshima J Med Sci; 2000 Mar 15; 49(1):73-82. PubMed ID: 10824460
    [Abstract] [Full Text] [Related]

  • 20. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA, DeBenedette MA, Watts TH, Berinstein NL.
    J Immunol; 1999 Apr 15; 162(8):5003-10. PubMed ID: 10202049
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.